IKT Inhibikase Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $260,501 | $123,440 | $3.10M |
| R&D expense | $29.79M | $17.21M | $13.62M | $12.03M | $11.36M |
| SG&A expense | $23.56M | $11.38M | $6.73M | $6.22M | $6.51M |
| Operating income | -$51.97M | -$28.59M | -$20.09M | -$18.13M | -$14.77M |
| Interest expense | — | — | — | — | $19,923 |
| Pretax income | -$48,259 | -$27,520 | — | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M |
| EBITDA | -$51.91M | -$28.56M | -$19.91M | -$18.12M | -$14.77M |
| EPS (basic) | -0.49 | -1.16 | -3.16 | -4.28 | -0.81 |
| EPS (diluted) | -0.49 | -1.16 | -3.16 | -4.28 | -0.81 |
| Weighted avg. shares (diluted) | 98.31M | 23.71M | 6.03M | 4.22M | 18.21M |
| Banking | |||||
| Net interest income | $3.72M | $1.07M | $1.06M | $74,453 | -$19,923 |
| Balance sheet | |||||
| Cash & equivalents | $139.22M | $56.49M | $9.17M | $7.19M | $40.75M |
| Short-term investments | $39.54M | $41.05M | $4.09M | $15.86M | $0 |
| Current assets | $180.11M | $98.45M | $14.21M | $24.37M | $42.47M |
| PP&E, net | $0 | $47,100 | $73,372 | $236,532 | $0 |
| Total assets | $181.20M | $98.60M | $14.51M | $24.94M | $42.47M |
| Current liabilities | $8.30M | $3.73M | $3.44M | $3.70M | $4.05M |
| Short-term debt | $0 | $110,517 | $150,095 | $145,836 | $0 |
| Long-term debt | — | — | $381,784 | — | $248,911 |
| Total debt | — | — | $531,879 | — | $248,911 |
| Total liabilities | $8.30M | $3.73M | $3.53M | $3.90M | $4.05M |
| Shareholders' equity | $172.90M | $94.87M | $10.98M | $21.04M | $38.42M |
| Net debt | — | — | -$8.63M | — | -$40.50M |
| Shares outstanding | 131.69M | 69.36M | 6.19M | 4.22M | 25.16M |
| Cash flow statement | |||||
| Operating cash flow | -$27.79M | -$19.15M | -$18.09M | -$17.35M | -$14.30M |
| Capital expenditure | $13,399 | $0 | $14,238 | $243,255 | $0 |
| Free cash flow | -$27.80M | -$19.15M | -$18.10M | -$17.59M | -$14.30M |
| Investing cash flow | $2.05M | -$37.00M | $11.66M | -$16.01M | $0 |
| Financing cash flow | $108.46M | $103.48M | $8.41M | -$204,769 | $41.09M |
| Depreciation & amortization | $60,499 | $26,272 | $177,398 | $6,723 | $0 |
| Stock-based compensation | $15.31M | $8.14M | $500,148 | $458,147 | $1.53M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.